PDF(Pubmed)
Abstract：
It has been suggested that the effect of coronavirus disease 2019 (COVID-19) booster vaccination in patients with B-cell non-Hodgkin\'s lymphoma (B-NHL) is inferior to that in healthy individuals. However, differences according to histological subtype or treatment status are unclear. In addition, there has been less research on patients who subsequently develop breakthrough infections. We investigated the effects of the first COVID-19 booster vaccination for patients with B-NHL and the clinical features of breakthrough infections in the Omicron variant era. In this study, B-NHL was classified into two histological subtypes: aggressive lymphoma and indolent lymphoma. Next, patients were subdivided according to treatment with anticancer drugs at the start of the first vaccination. We also examined the clinical characteristics and outcomes of patients who had breakthrough infections after a booster vaccination. The booster effect of the COVID-19 mRNA vaccine in patients with B-NHL varied considerably depending on treatment status at the initial vaccination. In the patient group at more than 1 year after the last anticancer drug treatment, regardless of the histological subtype, the booster effect was comparable to that in the healthy control group. In contrast, the booster effect was significantly poorer in the other patient groups. However, of the 213 patients who received the booster vaccine, 22 patients (10.3%) were infected with COVID-19, and 18 patients (81.8%) had mild disease; these cases included the patients who remained seronegative. Thus, we believe that booster vaccinations may help in reducing the severity of Omicron variant COVID-19 infection in patients with B-NHL.
摘要：
有人认为，冠状病毒病2019（COVID-19）加强疫苗接种对B细胞非霍奇金淋巴瘤（B-NHL）患者的影响不如健康个体。然而,根据组织学亚型或治疗状态的差异尚不清楚。此外,对随后发生突破性感染的患者的研究较少。我们调查了首次COVID-19加强疫苗接种对B-NHL患者的影响，以及Omicron变种时代突破性感染的临床特征。在这项研究中,B-NHL分为两种组织学亚型：侵袭性淋巴瘤和惰性淋巴瘤。接下来,根据首次疫苗接种开始时使用抗癌药物的治疗对患者进行细分.我们还检查了加强疫苗接种后发生突破性感染的患者的临床特征和结果。COVID-19mRNA疫苗对B-NHL患者的加强作用因初次接种时的治疗状态而异。在最后一次抗癌药物治疗后超过1年的患者组中，无论组织学亚型如何，加强效果与健康对照组相当.相比之下,其他患者组的强化效果明显较差.然而,在接受加强疫苗接种的213名患者中，22例（10.3％）感染了COVID-19，18例（81.8％）患有轻度疾病；这些病例包括血清阴性的患者。因此，我们认为,加强疫苗接种可能有助于降低B-NHL患者Omicron变异型COVID-19感染的严重程度.
